European Companies Search Engine
EU funding (€4,614,943): Ultrahigh-throughput exploration of metagenomic sequence space to discover and engineer novel biocatalysts and bioactive compounds Hor11 Jul 2025 EU Research and Innovation programme "Horizon"
Overview
Text
Ultrahigh-throughput exploration of metagenomic sequence space to discover and engineer novel biocatalysts and bioactive compounds
The objective of MetaExplore is to provide research training for young researchers in novel experimental as well as computational methods to fully exploit the immense biotechnological potential of metagenomic sequence space, with innovative approaches on both fronts. On the experimental side, successful screening of large metagenomic libraries requires ultrahigh-throughput technologies, because low hit rates can frustrate conventional experimental formats. Here microfluidic droplet screening (allowing >10e8 picolitre assays per day, at kHz rates) is used in various formats to derive fundamental insight and achieve valorisation, along with label-free mass-spectrometric screens and liquid handling robots. On the in silico side, unprecedented availability of sequence data (e.g. more than 3 billion ORFs in the database MGnify) and machine learning will provide systematic insights based in sequence interpretation. The combination of sequence-based and functional metagenomics is extraordinarily powerful and our training programme bridges the classical divide between them. These skill sets, together with environmental DNA resources (from polar regions, hot environments, soil, marine & fresh-water and gut libraries) support campaigns to identify useful protein reagents, for green technology applications (e. g. for microplastics degradation, glycobiology or fine chemical synthesis), and healthcare (e.g. as bacteriocidal reagents or therapeutic enzymes). 11 leading academic groups and 2 industrial partners will work together in MetaExplore (and 9 companies and universities as associated partners and advisors). The unified efforts of leading stakeholders in the field of metagenomics from Europe will provide a uniquely powerful multidisciplinary training environment with critical mass to facilitate the uptake of new technologies into applied research, exposing young researchers to typical intersectorial challenges in the exploration and sustainable exploitation of biodiversity.
Funded Companies:
| Company name | Funding amount |
| ArcticZymes AS | ? |
| Astrazeneca UK Ltd. | €348,738 |
| EUROPEAN MOLECULAR BIOLOGY LABORATORY | €580,545 |
| HUN-REN Szegedi Biologiai Kutatokozpont | €509,808 |
| Institut National des Sciences Appliquees de Toulouse | €314,669 |
| Janssen Pharmaceutica N.V. | €288,540 |
| Norges Teknisk-Naturvitenskapelige Universitet Ntnu | €339,932 |
| Sintef AS | €339,932 |
| The Chancellor Masters and Scholars of the University of Cambridge | €348,738 |
| United Kingdom Research and Innovation | €348,738 |
| Universidad Autonoma de Madrid | €564,376 |
| Universidad de Alicante | €282,188 |
| University College London | €348,738 |
Source: https://cordis.europa.eu/project/id/101226425
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Arcticzymes AS, Tromsø, Norway.
The visualizations for "ArcticZymes AS - EU funding (€4,614,943): Ultrahigh-throughput exploration of metagenomic sequence space to discover and engineer novel biocatalysts and bioactive compounds"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
